Gene Therapy for Localized Scleroderma Gets Rare Pediatric Designation – Rare Disease Report
CNA Finance |
Gene Therapy for Localized Scleroderma Gets Rare Pediatric Designation
Rare Disease Report One month after receiving a Rare Pediatric Disease Designation for its gene therapy, FCX-007 to treat epidermolysis bullosa, the U.S. Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation for FCX-013 to treat localized … Fibrocell’s gene therapy candidate FCX-013 nabs Rare Pediatric Disease Designation from FDA; shares ahead 9 …Seeking Alpha Fibrocell Receives Rare Pediatric Disease Designation from FDA for FCX-013 for Treatment of Localized SclerodermaGlobeNewswire (press release) FDA Designation A Boon For Fibrocell Science (FCSC)Economic Calendar CNA Finance (press release) all 12 news articles » |
|
A new wave of gene therapies ready to hit US shores
BioPharma Dive The first ever approved gene therapy was Shenzhen SiBiono GenTech’s Gendicine, a recombinant Ad-p53 gene therapy for head and neck cancer, which launched in China in 2004. But it was Glybera’s (alipogene tiparvovec) approval in fall 2012 that … |
|
5 Trends affecting gene therapy development
BioPharma Dive The premise — and often bragging point — of gene therapies is the idea that they are one-off cures. Rather than having patients take continuous doses of medicine their whole lives, gene therapy providers can just go in, insert, cut or replace the … |
NTV |
Pet Doctor: Immunotherapy Vaccine for Cancer
NTV Dr. Dennis Larsen discusses the immunotherapy vaccine for cancer in this week’s Pet Doctor (NTV News). AA. Cancer in pets is common in dogs but somewhat less common in cats. Of the estimated 70 million dogs in the U.S. approximately 6 million will get … |
Genetic Engineering & Biotechnology News |
Synthetic Biology Expands and Grows
Genetic Engineering & Biotechnology News Synthetic biology is an exciting and rapidly evolving field of research that can broadly be defined as the design (or redesign) and construction of novel artificial biological pathways, organisms, or devices. Applying engineering principles to … |
|
Vitamin C and antibiotics: A new one-two ‘punch’ for knocking-out cancer stem cells.
Science Daily The antibiotic, Doxycycline, followed by doses of ascorbic acid (Vitamin C), were surprisingly effective in killing the cancer stem cells under laboratory conditions, according to the research published in the journal Oncotarget. In boxing terms, this … Antibiotics and vitamin C could kill cancer cellsNHS Choices |